5303.5000 -72.50 (-1.35%)
NSE Aug 29, 2025 15:31 PM
Volume: 115.3K
 

5303.50
-1.35%
HDFC Securities
Maintain BUY with a revised TP of Rs 2,410 (24x FY20E EPS) Alkems 1QFY19 results were largely below our estimates. Revenue at Rs 16.7bn, was up 28.9%YoY and 10.3%QoQ. EBITDA of Rs 2.1bn grew 127%YoY with margin coming up to 12.8%, up 550bps YoY. PAT at Rs 1.4bn was 115% higher than that in 1QFY18. The impressive growth is attributed to a low GST-hit base. EBITDA, margin, and PAT missed our estimates by 21%, 380bps, and 22% YoY respectively. Domestic growth was 25.7%.
ICICI Securities Limited upgraded Alkem Laboratories Ltd. to Buy with a price target of 6065.0 on 13 Aug, 2025.
More from Alkem Laboratories Ltd.
Recommended